Polo-Like Kinase 1 as Predictive Marker and Therapeutic Target for Radiotherapy in Rectal Cancer
- 31 August 2010
- journal article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 177 (2), 918-929
- https://doi.org/10.2353/ajpath.2010.100040
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53Proceedings of the National Academy of Sciences of the United States of America, 2009
- The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1Current Biology, 2007
- BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In VivoCurrent Biology, 2007
- Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapyEuropean Journal of Surgical Oncology, 2006
- Patient-based cross-platform comparison of oligonucleotide microarray expression profilesLaboratory Investigation, 2005
- Polo-like kinases and the orchestration of cell divisionNature Reviews Molecular Cell Biology, 2004
- Identification of high risk breast-cancer patients by gene expression profilingThe Lancet, 2002
- Inhibition of Polo-like Kinase-1 by DNA Damage Occurs in an ATM- or ATR-dependent FashionPublished by Elsevier BV ,2001
- The Polo-like kinase Cdc5p and the WD-repeat protein Cdc20p/fizzy are regulators and substrates of the anaphase promoting complex in Saccharomyces cerevisiaeThe EMBO Journal, 1998
- Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes.The Journal of cell biology, 1996